
Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Larimar Therapeutics, Inc. (LRMR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.83, with a market capitalisation of $392.68M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.72 to $6.42. This page covers its latest market performance, valuation, price trends and company information.
$392.68M | |
$3.83 | |
$25.87 | |
$1.53 | |
$3.91 | |
-- | |
1.74M | |
-- | |
$6.42 | |
$2.72 | |
-- | |
-- |
Larimar Therapeutics, Inc. (LRMR) is trading at $3.83 in pre-market trading as of 2026-09-16 08:01:00, down 2.17% ($0.08) from the previous close of $3.91
Pre-market trading shows how investors are pricing LRMR before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Larimar Therapeutics, Inc. (LRMR) moved from $3.83 to $3.83, representing a decline of 0.13% ($0.00).
The stock traded between $3.70 and $4.17 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 1.06 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30.0%
LRMR is currently trading at $3.83, placing it 30.0% of the way from its 52-week low of $2.72 to its 52-week high of $6.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 71 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Larimar Therapeutics, Inc. (LRMR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.